Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus.
about
Viral double-stranded RNAs from vaccinia virus early or intermediate gene transcripts possess PKR activating function, resulting in NF-kappaB activation, when the K1 protein is absent or mutatedVirus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infectionTargeted infection of HIV-1 Env expressing cells by HIV(CD4/CXCR4) vectors reveals a potential new rationale for HIV-1 mediated down-modulation of CD4The evolution of poxvirus vaccinesHighly efficient induction of protective immunity by a vaccinia virus vector defective in late gene expressionImmunogenicity of the Plasmodium falciparum serine repeat antigen (p126) expressed by vaccinia virus.Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice.Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein.The human immunodeficiency virus type 1 gag gene encodes an internal ribosome entry site.Fusogenic selectivity of the envelope glycoprotein is a major determinant of human immunodeficiency virus type 1 tropism for CD4+ T-cell lines vs. primary macrophagesSimultaneous high-resolution analysis of vaccinia virus and host cell transcriptomes by deep RNA sequencingCell surface expression of the HIV-1 envelope glycoproteins is directed from intracellular CTLA-4-containing regulated secretory granules.An endoplasmic reticulum-targeting signal sequence enhances the immunogenicity of an immunorecessive simian virus 40 large T antigen cytotoxic T-lymphocyte epitope.Stringent chemical and thermal regulation of recombinant gene expression by vaccinia virus vectors in mammalian cells.A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40LCoadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity.Effect of the V3 loop deletion of envelope glycoprotein on cellular responses and protection against challenge with recombinant vaccinia virus expressing gp160 of primary human immunodeficiency virus type 1 isolates.Genome-wide analysis of the 5' and 3' ends of vaccinia virus early mRNAs delineates regulatory sequences of annotated and anomalous transcripts.Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity.NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.Determinants of human immunodeficiency virus type 1 envelope glycoprotein oligomeric structure.Human immunodeficiency virus type 1 envelope protein endocytosis mediated by a highly conserved intrinsic internalization signal in the cytoplasmic domain of gp41 is suppressed in the presence of the Pr55gag precursor proteinA novel antibody-dependent cellular cytotoxicity epitope in gp120 is identified by two monoclonal antibodies isolated from a long-term survivor of human immunodeficiency virus type 1 infectionControl of mucosal virus infection by influenza nucleoprotein-specific CD8+ cytotoxic T lymphocytesThe cytoplasmic and transmembrane domains of the vaccinia virus B5R protein target a chimeric human immunodeficiency virus type 1 glycoprotein to the outer envelope of nascent vaccinia virions.Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteersHigh-affinity T helper epitope induces complementary helper and APC polarization, increased CTL, and protection against viral infection.Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate.Comparative clonal analysis of human immunodeficiency virus type 1 (HIV-1)-specific CD4+ and CD8+ cytolytic T lymphocytes isolated from seronegative humans immunized with candidate HIV-1 vaccines.Crystallization of a trimeric human T cell leukemia virus type 1 gp21 ectodomain fragment as a chimera with maltose-binding protein.HIV-1 induces cytotoxic T lymphocytes in the cervix of infected women.Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes.The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope.Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function.Induction of tumor antigen-specific immunity in vivo by a novel vaccinia vector encoding safety-modified simian virus 40 T antigen.IL-15 as a mediator of CD4+ help for CD8+ T cell longevity and avoidance of TRAIL-mediated apoptosis.Enhanced cell surface expression, immunogenicity and genetic stability resulting from a spontaneous truncation of HIV Env expressed by a recombinant MVA.Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary HIV infectionMajor histocompatibility complex-restricted CD8+ cytotoxic T lymphocytes from horses with equine infectious anemia virus recognize Env and Gag/PR proteins.Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities.
P2860
Q24609947-6AA94ADD-7767-4093-BAD1-6C661AFA85A9Q24645815-0DF090BC-5D53-4FA9-A7E3-5A3041C2C9E5Q25257643-1CB894D0-796B-400F-B469-65F9A9E1C0F8Q26995905-61581FF8-F6AA-441B-B249-C25736009AC8Q27469703-136D7384-47C6-4C0B-82AE-C338B8177637Q33608668-FCC27C2E-EC08-4D1D-9357-199F6CE163BDQ33609436-6B2F3D25-2592-4D30-8C41-1365E0E4CC01Q33784928-3D1CCABF-C727-4B63-B6C6-1CAD8ACEDC28Q33834664-18D5929F-D9C0-48E4-9964-760D5C41CE48Q33944466-07DD1215-1322-4DBC-B3C6-E188104854A8Q33953053-7A995C8F-99AA-490E-965D-4228C5643A90Q34030981-BA74856F-A730-4461-AA01-8082B1206E94Q34069951-179058BB-3D27-44FA-8E5B-43484BC4F9C6Q34076617-97AB3359-692B-4C49-9C87-DEE8409B751EQ34191248-A994C3C4-09D2-40B1-A707-B1A7D575CBA5Q34869878-871BB1E3-73B5-4DA1-9D57-5E3EA70030B4Q34999946-027F955E-B12C-492F-998C-1CA306945466Q35076980-ADBBD132-A071-4102-9231-3B54F439547BQ35130248-21377EF1-25B6-445F-B265-B40A0FABC320Q35519418-FA9A4452-BC5A-49EF-9CFE-E1346C58CFF4Q35832875-1AE367E6-D181-4190-938F-7B769BB9A6C7Q35869312-E3956B51-CB49-4F3F-9C80-EF8D1CFBAC83Q35876233-393C6C73-5B87-4B02-9B2D-9E223ED49694Q35880528-FF9568C5-4535-4637-BAC2-165D7EE5278CQ35881351-25287BC6-0D89-4F77-A576-E67603566D04Q35997008-C87E8686-F4B9-4064-A313-21255C529C22Q36043015-6851F607-8F8B-4011-967B-994FE372E202Q36141610-DE20921B-4C4C-4151-BEB3-332F9E8C9F66Q36232089-D32D96F4-9B77-48BE-904B-16C040609B2BQ36281087-4F01C9C6-C861-4688-8563-1C67FA490357Q36376747-C12DE353-A458-4008-8547-7D69C170E815Q36376876-F0AE6E8E-A905-4C90-879F-06A0E21BC62EQ36401780-197FCC02-BF65-4580-8B2C-96FFF2ACC77EQ36402501-F827D966-091A-4209-A49E-EAEF2DF11980Q36473836-BC77782B-AE5E-42D0-952C-7EF168FE793AQ36516239-56AF3666-FB5F-4226-925E-B4162F1BB89DQ36532471-DB675F05-7C36-40C6-9C9C-55872344BD85Q36576849-F672A4C1-5F39-4C9D-9567-15767CEF5F15Q36628637-5D38162D-B541-450D-8A7D-FAF60895A14AQ36633402-F21F5EB3-61BA-4526-8E96-898FF7C9A521
P2860
Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus.
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
1990年论文
@zh
1990年论文
@zh-cn
name
Removal of cryptic poxvirus tr ...... a recombinant vaccinia virus.
@ast
Removal of cryptic poxvirus tr ...... a recombinant vaccinia virus.
@en
type
label
Removal of cryptic poxvirus tr ...... a recombinant vaccinia virus.
@ast
Removal of cryptic poxvirus tr ...... a recombinant vaccinia virus.
@en
prefLabel
Removal of cryptic poxvirus tr ...... a recombinant vaccinia virus.
@ast
Removal of cryptic poxvirus tr ...... a recombinant vaccinia virus.
@en
P2093
P2860
P1433
P1476
Removal of cryptic poxvirus tr ...... f a recombinant vaccinia virus
@en
P2093
P2860
P304
P407
P577
1990-05-01T00:00:00Z